touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.
The experts
This touchPODCAST is for healthcare professionals outside of the UK only
This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma